Neogenomics, Inc.
NEO
$16.28
$0.442.78%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 8.03% | -1.84% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 8.03% | -1.84% | |||
| Cost of Revenue | 3.75% | -0.95% | |||
| Gross Profit | 13.62% | -2.97% | |||
| SG&A Expenses | 2.39% | 2.45% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.58% | 0.72% | |||
| Operating Income | 43.97% | -39.71% | |||
| Income Before Tax | 110.39% | -41.69% | |||
| Income Tax Expenses | 12.71% | 81.31% | |||
| Earnings from Continuing Operations | 113.08% | -73.12% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 113.08% | -73.12% | |||
| EBIT | 43.97% | -39.71% | |||
| EBITDA | 758.97% | -126.22% | |||
| EPS Basic | 113.07% | -72.40% | |||
| Normalized Basic EPS | 44.46% | -45.78% | |||
| EPS Diluted | 113.07% | -72.40% | |||
| Normalized Diluted EPS | 44.95% | -45.78% | |||
| Average Basic Shares Outstanding | 0.36% | 0.40% | |||
| Average Diluted Shares Outstanding | 1.29% | 0.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||